Printer Friendly

Additional U.S. patent for stem cell technology.

PETACH TIKVAH, ISRAEL, April 10, 2014 -- BrainStorm Cell Therapeutics (OTCQB: BCLI) said that the U.S. Patent and Trademark Office has granted the company an additional patent for its autologous stem cell technology.

Patent No. 8,647,874 covers the production method of proprietary stem cells induced to secrete significantly elevated levels of neurotrophic factors for the treatment of neurodegenerative diseases.

The neurotrophic factors secreted by the company's patented cells include Glial Cell-Derived Neurotrophic Factor (GDNF), Brain-Derived Neurotrophic Factor (BDNF), and Vascular Endothelial Growth Factor (VEGF), known to support the neural cell network by protection of existing motor neurons, promotion of motor neuron growth, and re-establishment of nerve-muscle interaction.

In addition, the cells secrete high levels of Hepatocyte Growth Factor (HGF), which has been recently suggested to have neuroprotective effects in ALS.


COPYRIGHT 2014 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Patent News
Publication:Stem Cell Business News
Date:Apr 21, 2014
Previous Article:SBIR grant will aid development of novel way to isolate adipose stem cells.
Next Article:Joint patent on adipose stem cell platform technology.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters